Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Biotherapeutics, Inc.”

156 pharma patents match "Biotherapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 156
Index total 30,257
Page 2 / 7

Quick answer

This filtered view shows 156 pharmaceutical patents matching "Biotherapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

156 results for “Biotherapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12042558

    Method and formulation for improving roflumilast skin penetration lag time

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  2. US 12042487

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  3. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  4. US 12023355

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Iovance Biotherapeutics, Inc. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  5. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  6. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  7. US 12011437

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  8. US 12005052

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  9. US 12005051

    Topical roflumilast formulation having improved delivery and plasma half life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  10. US 11998568

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  11. US 11992480

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  12. US 11981921

    TIL expansion processes using specific cytokine combinations and/or AKTi treatment

    Iovance Biotherapeutics, Inc. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  13. US 11975066

    Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof

    SAB Biotherapeutics, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  14. US 11975028

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  15. US 11969444

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  16. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  17. US 11932695

    Modified antibodies and related compounds, compositions and methods of use

    Sensei Biotherapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  18. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Atara Biotherapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  19. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  20. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  21. US 11857573

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  22. US 11819517

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  23. US 11819496

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  24. US 11793796

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted